Advanced

New pharmacologic targets for the treatment of the overactive bladder: an update.

Andersson, Karl-Erik LU (2004) In Urology 63(3 Suppl 1). p.32-41
Abstract
Although currently available antimuscarinic agents are the standard of care for overactive bladder (OAB), they are limited by certain side effects, particularly dry mouth and constipation. Research aimed at discovering new therapies for OAB has resulted in the identification of some promising drugs. Investigations of pharmacologic targets in the central nervous system (CNS) have yielded encouraging results with several agents, including tramadol and gabapentin. Further investigation may show that drugs acting at serotonergic and noradrenergic CNS sites are clinically useful as therapies for OAB. Some peripherally acting drugs, such as resiniferatoxin and botulinum toxin, have already been proved to be of clinical value. However,... (More)
Although currently available antimuscarinic agents are the standard of care for overactive bladder (OAB), they are limited by certain side effects, particularly dry mouth and constipation. Research aimed at discovering new therapies for OAB has resulted in the identification of some promising drugs. Investigations of pharmacologic targets in the central nervous system (CNS) have yielded encouraging results with several agents, including tramadol and gabapentin. Further investigation may show that drugs acting at serotonergic and noradrenergic CNS sites are clinically useful as therapies for OAB. Some peripherally acting drugs, such as resiniferatoxin and botulinum toxin, have already been proved to be of clinical value. However, development of other agents that block afferent or efferent nerve impulses in the bladder through activity at vanilloid, purinergic, or opioid-like receptor sites may result in clinically useful drugs. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Urology
volume
63
issue
3 Suppl 1
pages
32 - 41
publisher
Elsevier
external identifiers
  • pmid:15013650
  • wos:000220375300006
  • scopus:1542298219
ISSN
1527-9995
DOI
10.1016/j.urology.2003.10.005
language
English
LU publication?
yes
id
df27e7cc-454f-4b76-8845-2db6e6995f75 (old id 121368)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15013650&dopt=Abstract
date added to LUP
2007-07-04 14:57:47
date last changed
2017-04-09 03:37:59
@article{df27e7cc-454f-4b76-8845-2db6e6995f75,
  abstract     = {Although currently available antimuscarinic agents are the standard of care for overactive bladder (OAB), they are limited by certain side effects, particularly dry mouth and constipation. Research aimed at discovering new therapies for OAB has resulted in the identification of some promising drugs. Investigations of pharmacologic targets in the central nervous system (CNS) have yielded encouraging results with several agents, including tramadol and gabapentin. Further investigation may show that drugs acting at serotonergic and noradrenergic CNS sites are clinically useful as therapies for OAB. Some peripherally acting drugs, such as resiniferatoxin and botulinum toxin, have already been proved to be of clinical value. However, development of other agents that block afferent or efferent nerve impulses in the bladder through activity at vanilloid, purinergic, or opioid-like receptor sites may result in clinically useful drugs.},
  author       = {Andersson, Karl-Erik},
  issn         = {1527-9995},
  language     = {eng},
  number       = {3 Suppl 1},
  pages        = {32--41},
  publisher    = {Elsevier},
  series       = {Urology},
  title        = {New pharmacologic targets for the treatment of the overactive bladder: an update.},
  url          = {http://dx.doi.org/10.1016/j.urology.2003.10.005},
  volume       = {63},
  year         = {2004},
}